CN116829187A - 纤维化进展的抑制剂 - Google Patents
纤维化进展的抑制剂 Download PDFInfo
- Publication number
- CN116829187A CN116829187A CN202180091901.4A CN202180091901A CN116829187A CN 116829187 A CN116829187 A CN 116829187A CN 202180091901 A CN202180091901 A CN 202180091901A CN 116829187 A CN116829187 A CN 116829187A
- Authority
- CN
- China
- Prior art keywords
- ser
- thr
- fibrosis
- seq
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPPCT/JP2020/044406 | 2020-11-30 | ||
| PCT/JP2020/044406 WO2022113316A1 (ja) | 2020-11-30 | 2020-11-30 | 線維化の進行抑制剤 |
| PCT/JP2021/043543 WO2022114165A1 (ja) | 2020-11-30 | 2021-11-29 | 線維化の進行抑制剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116829187A true CN116829187A (zh) | 2023-09-29 |
Family
ID=81754505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180091901.4A Pending CN116829187A (zh) | 2020-11-30 | 2021-11-29 | 纤维化进展的抑制剂 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240084020A1 (https=) |
| EP (1) | EP4252771A4 (https=) |
| JP (3) | JPWO2022113316A1 (https=) |
| KR (1) | KR20230114698A (https=) |
| CN (1) | CN116829187A (https=) |
| AU (1) | AU2021385871A1 (https=) |
| CA (1) | CA3199351A1 (https=) |
| CL (1) | CL2023001460A1 (https=) |
| IL (1) | IL303159A (https=) |
| MX (1) | MX2023006164A (https=) |
| TW (1) | TW202237182A (https=) |
| WO (2) | WO2022113316A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5954916B1 (ja) | 2015-04-14 | 2016-07-20 | 中外製薬株式会社 | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
| MX2022005654A (es) | 2019-11-20 | 2022-06-22 | Chugai Pharmaceutical Co Ltd | Preparacion que contiene anticuerpo. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5954916B1 (ja) * | 2015-04-14 | 2016-07-20 | 中外製薬株式会社 | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
-
2020
- 2020-11-30 WO PCT/JP2020/044406 patent/WO2022113316A1/ja not_active Ceased
- 2020-11-30 JP JP2021531123A patent/JPWO2022113316A1/ja not_active Withdrawn
-
2021
- 2021-11-29 IL IL303159A patent/IL303159A/en unknown
- 2021-11-29 AU AU2021385871A patent/AU2021385871A1/en active Pending
- 2021-11-29 EP EP21898137.1A patent/EP4252771A4/en active Pending
- 2021-11-29 MX MX2023006164A patent/MX2023006164A/es unknown
- 2021-11-29 TW TW110144377A patent/TW202237182A/zh unknown
- 2021-11-29 US US18/038,460 patent/US20240084020A1/en active Pending
- 2021-11-29 CN CN202180091901.4A patent/CN116829187A/zh active Pending
- 2021-11-29 CA CA3199351A patent/CA3199351A1/en active Pending
- 2021-11-29 KR KR1020227005324A patent/KR20230114698A/ko active Pending
- 2021-11-29 JP JP2022500682A patent/JPWO2022114165A1/ja not_active Withdrawn
- 2021-11-29 WO PCT/JP2021/043543 patent/WO2022114165A1/ja not_active Ceased
-
2022
- 2022-04-15 JP JP2022067622A patent/JP7802601B2/ja active Active
-
2023
- 2023-05-22 CL CL2023001460A patent/CL2023001460A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230114698A (ko) | 2023-08-01 |
| EP4252771A4 (en) | 2024-10-23 |
| JP2022095913A (ja) | 2022-06-28 |
| CA3199351A1 (en) | 2022-06-02 |
| TW202237182A (zh) | 2022-10-01 |
| MX2023006164A (es) | 2023-07-28 |
| WO2022114165A1 (ja) | 2022-06-02 |
| IL303159A (en) | 2023-07-01 |
| JPWO2022114165A1 (https=) | 2022-06-02 |
| WO2022113316A1 (ja) | 2022-06-02 |
| US20240084020A1 (en) | 2024-03-14 |
| AU2021385871A9 (en) | 2024-05-02 |
| JP7802601B2 (ja) | 2026-01-20 |
| AU2021385871A1 (en) | 2023-06-22 |
| CL2023001460A1 (es) | 2023-12-01 |
| JPWO2022113316A1 (https=) | 2022-06-02 |
| EP4252771A1 (en) | 2023-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lim et al. | Diet‐induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism | |
| Yin et al. | Enhanced liver regeneration in IL-10–Deficient mice after partial hepatectomy via stimulating inflammatory response and activating hepatocyte STAT3 | |
| US20060039910A1 (en) | Methods and compositions for treating allergic inflammation | |
| JP2009526756A (ja) | Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法 | |
| CN114306593A (zh) | 用于抑制有需要的受试者的纤维化的方法 | |
| CN115335120A (zh) | 用于治疗和/或预防冠状病毒诱导的急性呼吸窘迫综合征的抑制masp-2的方法 | |
| AU2006236755A1 (en) | Methods for treating and preventing fibrosis by IL-21 / IL-21R antagonists | |
| TWI363091B (en) | Uses of mammalian cytokine; related reagents | |
| JP7802601B2 (ja) | 線維化の進行抑制剤 | |
| JP5210156B2 (ja) | 炎症性疾患の検出並びに炎症性疾患の予防又は治療用組成物 | |
| Zheng et al. | C5a/C5aR1 mediates IMQ‐induced psoriasiform skin inflammation by promoting IL‐17A production from γδ‐T cells | |
| KR101589742B1 (ko) | 건성 안 증후군 치료를 위한 갈렉틴의 조성물 및 용도 | |
| Lee et al. | Poly-γ-glutamic acid suppresses osteoclastogenesis in human osteoclast precursors and prevents joint damage in a collagen-induced murine arthritis model | |
| CN101730545A (zh) | 用于治疗肾病的化合物和方法 | |
| JP2018510870A (ja) | Ｂ７リガンド二量体界面に由来する単離されたペプチドおよびそれらの使用 | |
| Tardif1BDE et al. | Involvement of interleukin-18 in the inflammatory response against oropharyngeal candidiasis | |
| HK40092050A (zh) | 纤维化进展的抑制剂 | |
| US20170333529A1 (en) | Neuregulin in the treatment of fibrotic disorders | |
| EA050619B1 (ru) | Ингибитор прогрессирования фиброза | |
| Gao et al. | Complement C3 deficiency prevent against the onset of streptozotocin-induced autoimmune diabetes involving expansion of regulatory T cells | |
| Li et al. | CD200-CD200R1 signalling attenuates imiquimod-induced psoriatic inflammation by inhibiting the activation of skin inflammatory macrophages | |
| WO2024028448A1 (en) | Il-15 inhibitors useful for the treatment of atopic dermatitis | |
| CN113975372A (zh) | 一种采用激动剂抑制银屑病的方法 | |
| WO2024011946A1 (en) | Polypeptide dimers for the treatment of systemic sclerosis | |
| Alvarado et al. | Dual targeting of mast cells and TSLP with a bispecific antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40092050 Country of ref document: HK |